CXCR3／CXCL10在乳腺癌中的表达及临床意义

目的探讨趋化因子受体3（CXCR3）及趋化因子配体10（CXCL10）在乳腺癌中的表达及临床意义。方法采用免疫组织化学SP法及二步法对60例乳腺癌组织、20例乳腺纤维瘤组织及20例乳腺腺病组织分别进行CXCR3、CXCL10检测。结果乳腺癌中CXCR3（40／60，66．7％）、CXCL10（45／60，75％）的表达高于乳腺腺病CXCR3（8／20，40％）X^2=4．44，P=0．035；CXCL10（10／20，50％）x。=4．36，P=0．037）]，乳腺癌中CXCR3的表达与有无腋窝淋巴结转移、临床分期、HER-2的表达有关（X^2=4．15，P=0．042；X^2=7．74，P：0．021；X^2=4．27，P=0．039），且CXCR3的表达强度与腋窝淋巴结转移数及临床分期目呈正相关（-=0．375，P=0．003；t=0．451，P=0．000）。结论CXCR3可能与乳腺癌的进展及早期转移有关，CXCR3可能作为乳腺癌的一个预后指标。

The expression and clinical significance of CXCR3/CXCL10 in human breast cancer

Objective To investigate the expression and clinical significance of CXCR3/CXCL10in human cancer.Methods CXCR3 and CXCL10 were detected in 60 paraffinic tissues of patients with primary breast cancer,20 of mammary fibroma and 20 of mastopathy by immunohistochemistry S-P method and two stage method.Results The expression of CXCR3 (40/60,66.7％ ) and CXCL10 (45/60,75％)in breast cancer was higher than that in mastopathy CXCR3(8/20,40％ )x2 =4.44,P =0.035 ;CXCL10( 10/20,50％ )x2 =4.36,P =0.037)].The expression of CXCR3 was related to status of axillary lymph node metastasis,clinical stage and the expression of HER-2 (x2 =4.15,P =0.042; x2 =7.74,P =0.021 ;x2 =4.27,P =0.039).The expression of CXCR3 had positive relationship to the number axillary lymph node metastasis( rs =0.375,P =0.003 ),clinical stage ( rs =0.451,P =0.000).Conclusions CXCR3 may be related to the progression and metastasis of breast cancer,and it may be used as a marker of breast cancer prognosis.